Table 2.
Treatment | HFNC Group | NIPPV group | |
---|---|---|---|
pH | Before | 7.21 ± 0.03 | 7.23 ± 0.03 |
After | 7.38 ± 0.04a | 7.34 ± 0.03a | |
PaCO2 | Before | 63.97 ± 4.79 | 63.68 ± 4.81 |
After | 51.63 ± 3.32b,c | 55.61 ± 3.47b | |
PaO2 | Before | 54.15 ± 2.74 | 54.22 ± 2.69 |
After | 77.94 ± 3.51b,c | 68.24 ± 2.67b | |
PaO2/FiO2 | Before | 158.21 ± 20.89 | 158.38 ± 21.46 |
After | 254.97 ± 18.45b | 249.98 ± 17.14b | |
Before | 33.06 ± 5.17 | 30.88 ± 4.87 | |
After | 26.81 ± 4.35a,c | 26.49 ± 4.24a | |
Intubation rate (%) | 2.78 | 2.78 |
Data are mean ± SD. n = 36. Comparison with before treatment: aP < 0.05; bP < 0.01 (paired t-test); comparison with the control group: cP < 0.05; dP < 0.01 (unpaired t-test).
HFNC, high-flow nasal cannula; non-invasive positive-pressure ventilator.